Protinhi Therapeutics is developing antivirals based on a proven mechanism of action in diseases such as HIV and Hepatitis C. The Protinhi lead programs focus on dengue and related viral diseases such as Zika and WestNile virus. The current COVID-19 pandemic has demonstrated the importance of developing strategies against upcoming viral diseases.
Johnson & Johnson Innovation – JLABS (JLABS) is a premier life science incubator program with a global network of open innovation ecosystems, enabling and empowering innovators with the aim to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare potential solutions to patients and consumers.
Joining the JLABS network will empower us further to accelerate the delivery of our proprietary compounds into novel drugs with the aim to address the current high unmet medical need against upcoming viral diseases such as COVID-10, dengue and WestNile virus.
“Being part of the Johnson & Johnson Innovation – JLABS ecosystem is a big and exciting step for us, we believe it will strengthen our R&D efforts and give us access to the additional expertise and mentorship.” states Dr. Bernd van Buuren, co-founder and CEO of Protinhi Therapeutics. “Protinhi has been able to demonstrate the strength and scalability of its technology platform by having potent leads acting against Corona. We have very promising results demonstrating blocked virus replication in cellular models for dengue, West Nile and SARS-CoV2. This shows the potential of the compounds as broad-spectrum antivirals. Our team has the competence and experience to develop them into innovative antiviral therapeutics.”